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I read with interest the article by Kao and colleagues [1] in
which the authors investigated the role of open lung biopsy in
patients with early-stage acute respiratory distress syndrome
(ARDS) of suspected non-infectious origin.
A point that merits attention is the need to differentiate
between ARDS and acute interstitial pneumonia (AIP). AIP is
a rapidly progressive idiopathic interstitial pneumonia charac-
terized by the presence of an organizing form of diffuse
alveolar damage on histopathological examination of lung
specimens. Although the histological pattern is indistinguish-
able from that found in ARDS, the term AIP is reserved for
cases of unknown cause [2]. In fact, exclusion of a precipita-
ting or etiological agent (which is usually identifiable in
patients with ARDS) is one of the diagnostic criteria for AIP.
The mortality from AIP is about 70% and is higher than that
from ARDS [3].
Although there are no established therapies for AIP,
parenteral corticosteroids, often at high doses, are used
frequently. Recently Suh and colleagues [4] reported survival
rates of 80% in a small series of ten patients with AIP, all of
whom required mechanical ventilation (with a median positive
end-expiratory pressure of 11 cmH2O) and underwent open
lung biopsy (on median hospital day 4). In these patients,
high-dose corticosteroid pulse therapy had been initiated (on
median hospital day 3.5) after respiratory infection had been
ruled out by means of an aggressive diagnostic workup
(including bronchoalveolar lavage performed on median
hospital day 2). The authors had postulated that the approach
of aggressive diagnostics, mechanical ventilation with lung-
protective strategy, and early institution of high-dose
immunosuppressive therapy could have led to the improved
clinical outcome [4].
In the present study, diffuse alveolar damage was seen in
most of the patients who had a non-specific pathological
diagnosis. Moreover, this group, in comparison with the
group with a specific diagnosis, had a higher rate of
treatment alteration (87% versus 56%) as well as a higher
rate of hospital survival (61% versus 33%). It is possible that
the trend toward improved survival that was seen in this
group was a reflection of the possibility that some of these
patients had AIP (rather than ARDS) and benefited from the
early administration of high-dose corticosteroids.
Letter
AIP or ARDS? Not just semantics
Navneet Singh
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Sector-12, Chandigarh-160012, India
Corresponding author: Navneet Singh, navneetchd@yahoo.com
Published: 29 September 2006 Critical Care 2006, 10:423 (doi:10.1186/cc5003)
This article is online at http://ccforum.com/content/10/5/423
© 2006 BioMed Central Ltd
See related research by Kao et al., http://ccforum.com/content/10/4/R106
AIP = acute interstitial pneumonia; ARDS = acute respiratory distress syndrome.
Authors’ response
Kuo-Chin Kao, Ying-Huang Tsai and Chung-Chi Huang
We appreciate Dr Singh’s interest in our article [1] and his
comments. The term ‘acute interstitial pneumonia (AIP)’ is
reserved for ARDS of unknown cause. The critical point in the
diagnosis of AIP is to exclude all possible etiologies using the
available methods. However, there is no standard laboratory
protocol for investigating all possible etiologies. Actually, the
diagnostic rate for AIP depends on how aggressive the
diagnostic approach is, such as open lung biopsy in ARDS
patients.
Some studies have found that the survival rate for AIP was
higher than for non-AIP ARDS patients [4,5]. Furthermore,
high-dose pulse corticosteroid treatment combined with a
lung-protective mechanical strategy could improve the clinical
outcome in AIP [4]. Recently the ARDS Clinical Trials
Network reported that there was no survival benefit when
corticosteroid was administered to ARDS patients beyond
7 days, but there was an improvement in cardiopulmonary
physiology [6]. However, in the subgroup in whomPage 2 of 2
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corticosteroid treatment was begun 7 to 13 days after the
onset of ARDS, the mortality rate was 25% lower than in the
placebo group, although this did not have statistical
significance. In that study [6], the percentage of patients with
ARDS due to unknown causes was not mentioned and
should have been very low (the category ‘other’ was only
12%). It is reasonable to assume that different etiologies
should be treated with different strategies in heterogeneous
ARDS patients, such as AIP and non-AIP patients.
In conclusion, AIP should be identified as soon as possible in
ARDS patients. In patients with disease due to unknown
causes, the corticosteroid response and outcome seem
better than in the ‘known cause’ ARDS patients. Open lung
biopsy is therefore indicated to diagnose AIP in some
selected early-stage ARDS patients. We recommend that a
prospective, randomized controlled trial be performed to
confirm this contention.
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